DWI-FLAIRミスマッチによる後期窓期脳卒中のためのテネクテプラーゼ (TRUST-MISMATCH)
DWI-FLAIRミスマッチに基づく4.5~9時間ウィンドウにおける急性虚血性脳卒中に対するテネクテプラーゼ血栓溶解療法:多施設共同前向き無作為化二重盲検プラセボ対照試験
The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:
- Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?
- The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.
Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.
Participants will be randomly assigned (1:1) immediately after randomization:
- Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).
- Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.
調査の概要
状態
状態
条件
条件
詳細な説明
Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours.
In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well >4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain.
TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Bo Song, MD
- 電話番号:+86-371-66278068
- メール:fccsongb@zzu.edu.cn
研究場所
-
-
Henan
-
Zhengzhou、Henan、中国、450052
- 募集
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan
-
コンタクト:
- Bo Song, MD
- 電話番号:+86-371-66278068
- メール:fccsongb@zzu.edu.cn
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Age ≥ 18 years;
-
AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);
-
Imaging criteria:
- DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
- DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
-
NIHSS score 4-25;
-
First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);
-
Signed informed consent from the patient or legally authorized representative.
Exclusion Criteria:
- Planned endovascular treatment;
- Contradictory to MRI examination;
- MRI image not qualified for evaluation;
- Obvious head injuries or strokes within 3 months;
- Subarachnoid or intracranial hemorrhage;
- History of intracranial hemorrhage;
- Intracranial tumor, arteriovenous malformation or aneurysm;
- Intracranial or spinal cord surgery within 3 months;
- Active internal hemorrhage;
- platelet count of <100000/mm3;
- Aortic arch dissection;
- Heparin therapy within 24 hours;
- Oral warfarin is being taken and INR>1.6 or APTT abnormal;
- Oral anticoagulation therapy;
- Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
- Blood glucose < 50 mg/dl (2.7mmol/L);
- Pregnancy;
- Neurological deficit after epileptic seizures;
- Major surgery within 1 month;
- Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
- Myocardial infarction within 3 months;
- Allergy to study drugs;
- Unlikely to adhere to the trial protocol or follow-up;
- Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
- Participation in other interventional clinical trials within the previous 3 months.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Tenecteplase group:
Patients will receive tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg) immediately after randomization.From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke. |
TNK-tPA (0.25 mg/kg, to maximum of 25mg) Asprin (placebo) TNK-tPA (placebo) |
|
アクティブコンパレータ:Control group
Patients will receive asprin(300mg) plus intravenous TNK(placebo, 0.25mg/kg, a maximum of 25 mg) immediately after randomization. From day 2 to day 90, patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke. |
Asprin (placebo) TNK-tPA (placebo) Asprin (300mg) |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Modified Rankin Scale (mRS)
時間枠:90 ± 7 days
|
Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days. |
90 ± 7 days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Modified Rankin Scale (mRS)
時間枠:90 ± 7 days
|
Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days. |
90 ± 7 days
|
|
Modified Rankin Scale (mRS)
時間枠:90 days
|
Ordinal shift analysis of mRS at 90 days |
90 days
|
|
National Institutes of Health Stroke Scale (NIHSS)
時間枠:72 hours and 7 ± 1 days (or at discharge)
|
Proportion of subjects with an improvement in NIHSS score of ≥2 points from baseline. |
72 hours and 7 ± 1 days (or at discharge)
|
|
National Institutes of Health Stroke Scale (NIHSS)
時間枠:72 hours and 7 ± 1 days (or at discharge)
|
Proportion of subjects achieving an NIHSS score of ≤1. |
72 hours and 7 ± 1 days (or at discharge)
|
|
Barthel (BI)
時間枠:90 ± 7 days
|
Barthel Index score at 90 ± 7 days. |
90 ± 7 days
|
|
EuroQol 5-Dimension (EQ-5D)
時間枠:90 ± 7 days
|
Quality of life measured by EQ-5D scale at 90 ± 7 days. |
90 ± 7 days
|
|
Modified Rankin Scale (mRS)
時間枠:90 ± 7 days
|
|
90 ± 7 days
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Symptomatic intracranial hemorrhage (sICH)
時間枠:36 hours
|
Proportion of subjects with symptomatic intracranial hemorrhage (sICH) within 36 hours (according to the ECASS III criteria for the primary safety analysis, with SITS-MOST and Heidelberg definitions used for supportive analyses). |
36 hours
|
|
Death
時間枠:90 days
|
Overall mortality rate at 90 days. |
90 days
|
|
Systemic bleeding
時間枠:90 days
|
Systemic bleeding at 90 days (according to the GUSTO criteria) |
90 days
|
|
Adverse events (AEs)/ serious adverse events (SAEs)
時間枠:90 ± 7 days
|
Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 ± 7 days. |
90 ± 7 days
|
|
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
時間枠:90 ± 7 days
|
Proportion of subjects experiencing MACCE (defined as ischemic stroke, hemorrhagic stroke, transient ischemic attack, myocardial infarction, or vascular death). |
90 ± 7 days
|
協力者と研究者
捜査官
捜査官
- スタディチェア:Bo Song, MD、Department of Neurology, the First Affiliated Hospital of Zhengzhou University
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- MISMATCH-001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。